Previsioni di mercato dell\'epilessia in America centrale e meridionale fino al 2030 - Analisi regionale - per tipo (epilessia mioclonica progressiva, epilessia riflessa, epilessia generalizzata e altre), via di somministrazione (orale, parenterale e altre), tipo di trattamento (farmaci di prima generazione, farmaci di seconda generazione e farmaci di terza generazione), fascia d\'età (adulti e bambini) e canale di distribuzione (farmacie ospedaliere, farmacie al dettaglio e altre)

BMIRE00030802 | Pages: 136 | Pharmaceuticals | Sep 2024 | Type: Regional | Status: Published

Il mercato dell\'epilessia in America centrale e meridionale è stato valutato a 593,56 milioni di dollari nel 2022 e si prevede che raggiungerà i 758,65 milioni di dollari entro il 2030; si stima che registrerà un CAGR del 3,1% dal 2022 al 2030.

L\'aumento dei programmi di sensibilizzazione condotti dalle organizzazioni alimenta il mercato dell\'epilessia in America centrale e meridionale

La crescente consapevolezza sull\'epilessia, sui suoi sintomi e sull\'importanza della diagnosi precoce ha portato a un aumento dei pazienti che cercano assistenza medica. Organizzazioni come l\'Epilepsy Foundation, l\'Epilepsy Society, l\'American Epilepsy Society e l\'Epilepsy Association of Central Florida svolgono un ruolo cruciale nell\'educazione delle persone su questa malattia. Il coinvolgimento di queste organizzazioni ha portato a un aumento dei tassi di diagnosi e a una popolazione di pazienti più ampia che necessita di cure per l\'epilessia. Numerose campagne di sensibilizzazione sono condotte da organizzazioni in tutto il mondo per diffondere la consapevolezza sulla condizione e sui trattamenti disponibili. In Brasile, la Lega brasiliana per l\'epilessia (LBE) conduce campagne di sensibilizzazione a livello nazionale durante il mese di sensibilizzazione sull\'epilessia. Organizza eventi, distribuisce materiale didattico e collabora con i media per aumentare la consapevolezza sull\'epilessia e ridurre lo stigma. Pertanto, tali iniziative e campagne di sensibilizzazione determinano un aumento delle diagnosi e dei trattamenti per l\'epilessia, offrendo opportunità di crescita redditizie al mercato.

Panoramica del mercato dell\'epilessia in America centrale e meridionale

Il mercato dell\'epilessia in America centrale e meridionale include un\'analisi a livello nazionale di Brasile, Argentina e il resto dell\'America centrale e meridionale. Si prevede che il Brasile avrà una quota di mercato significativa in questa regione. Secondo l\'Organizzazione panamericana della sanità, c\'è un divario di trattamento in America Latina, America meridionale e nei Caraibi, ovvero è superiore al 50%. Negli ultimi anni, i paesi hanno rafforzato la loro attenzione sulle malattie non trasmissibili, tra cui l\'epilessia. Secondo l\'articolo dell\'International Journal of Public Health pubblicato nel 2023, nel 2019 nei paesi del Sud e Centro America sono stati attribuiti all\'epilessia 1.375.066 anni di vita persi per disabilità (DALY), con una maggiore incidenza negli uomini.

Fatturato e previsioni del mercato dell\'epilessia in Sud e Centro America fino al 2030 (milioni di $ USA)

Segmentazione del mercato dell\'epilessia in Sud e Centro America

Il mercato dell\'epilessia in Sud e Centro America è suddiviso in base a tipo, via di somministrazione, tipo di trattamento, fascia d\'età, canale di distribuzione e paese.

In base al tipo, il mercato dell\'epilessia in Sud e Centro America è suddiviso in epilessia mioclonica progressiva, epilessia riflessa, epilessia generalizzata e altro. Il segmento dell\'epilessia generalizzata ha detenuto la quota di mercato più grande nel 2022.

In termini di via di somministrazione, il mercato dell\'epilessia del Sud e Centro America è suddiviso in orale, parenterale e altri. Il segmento orale ha detenuto la quota di mercato più grande nel 2022.

In base al tipo di trattamento, il mercato dell\'epilessia del Sud e Centro America è suddiviso in farmaci di prima generazione, farmaci di seconda generazione e farmaci di terza generazione. Il segmento dei farmaci di terza generazione ha detenuto la quota di mercato più grande nel 2022.

In base alla fascia d\'età, il mercato dell\'epilessia del Sud e Centro America è suddiviso in adulti e bambini. Il segmento degli adulti ha detenuto una quota di mercato maggiore nel 2022.

In termini di canale di distribuzione, il mercato dell\'epilessia del Sud e Centro America è suddiviso in farmacie ospedaliere, farmacie al dettaglio e altri. Il segmento delle farmacie ospedaliere ha detenuto la quota di mercato maggiore nel 2022.

Per paese, il mercato dell\'epilessia del Sud e Centro America è segmentato in Brasile, Argentina e resto del Sud e Centro America. Il Brasile ha dominato la quota di mercato dell\'epilessia del Sud e Centro America nel 2022.

Abbott Laboratories, Pfizer Inc, Eisai Co Ltd, UCB SA, LivaNova Plc, Novartis AG, Medtronic Plc, GSK Plc e H. Lundbeck AS sono alcune delle aziende leader che operano nel mercato dell\'epilessia del Sud e Centro America.

TABLE OF CONTENTS

 

1. Introduction

1.1 The Insight Partners Research Report Guidance

1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

2.2 Market Attractiveness

3. Research Methodology

3.1 Coverage

3.2 Secondary Research

3.3 Primary Research

4. Pipeline Studies for Epilepsy Therapy Approaches

4.1 Pipeline Studies for Epilepsy Therapy Approaches

4.1.1 Cell and Gene Therapy Approaches

4.1.2 Encapsulated cell bio delivery (ECB) system

4.1.3 Gene Therapy for Epilepsy Clinical Overview

4.1.3.1 Genetic Therapies Adopted for Clinic Research of Epilepsy

4.1.3.1.1 Gene Supplementation - Overview

4.1.3.1.2 Gene Modulation - Overview

4.1.3.1.3 Antisense Oligonucleotides and RNA Interference - Overview

4.1.3.1.4 Neuropeptides - Overview

4.1.3.1.5 Engineered Channels - Overview

4.1.3.1.6 Endogenous Channels - Overview

4.1.3.2 Pipeline Studies of Viral Vectors for Epilepsy

4.1.3.3 Pipeline Studies of Non-Viral Vectors for Epilepsy

4.1.3.3.1 Polymer-based Non-Viral Vectors for Epilepsy

4.1.3.3.2 Lipid-based Non-Viral Vectors for Epilepsy

4.1.3.4 Adeno-Associated Virus (AAV)-Mediated Neuromodulatory Peptides - Overview

4.1.3.5 Neurotrophic Factors for Gene Therapy Approaches

4.1.3.6 Potassium Channels for Human Epileptic Phenotypes

4.1.3.7 Enzyme Inducing Antiepileptic Drugs

5. South & Central America Epilepsy Market - Key Market Dynamics

5.1 Market Drivers

5.1.1 Rising Prevalence of Epilepsy

5.1.2 Increasing Investments in Development of Epilepsy Therapies

5.2 Market Restraints

5.2.1 Recall of Products

5.3 Market Opportunities

5.3.1 Surge in Awareness Programs Conducted by Organizations

5.4 Future Trends

5.4.1 Gene Therapy as Promising Treatment Approach

5.5 Impact of Drivers and Restraints:

6. Epilepsy Market - South & Central America Analysis

6.1 South & Central America: Epilepsy Market

7. South & Central America Epilepsy Market Analysis - by Type

7.1 Overview

7.2 Progressive Myoclonic Epilepsy

7.2.1 Overview

7.2.2 Progressive Myoclonic Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

7.3 Reflex Epilepsy

7.3.1 Overview

7.3.2 Reflex Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

7.4 Generalized Epilepsy

7.4.1 Overview

7.4.2 Generalized Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

7.5 Other

7.5.1 Overview

7.5.2 Other: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

8. South & Central America Epilepsy Market Analysis - by Route of Administration

8.1 Overview

8.2 Oral

8.2.1 Overview

8.2.2 Oral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

8.3 Parenteral

8.3.1 Overview

8.3.2 Parenteral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

8.4 Others

8.4.1 Overview

8.4.2 Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

9. South & Central America Epilepsy Market Analysis - by Treatment Type

9.1 Overview

9.2 First Generation Drugs

9.2.1 Overview

9.2.2 First Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

9.3 Second Generation Drugs

9.3.1 Overview

9.3.2 Second Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

9.4 Third Generation Drugs

9.4.1 Overview

9.4.2 Third Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

10. South & Central America Epilepsy Market Analysis - by Age Group

10.1 Overview

10.2 Adult

10.2.1 Overview

10.2.2 Adult: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

10.3 Children

10.3.1 Overview

10.3.2 Children: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

11. South & Central America Epilepsy Market Analysis - by Distribution Channel

11.1 Overview

11.2 Hospital Pharmacies

11.2.1 Overview

11.2.2 Hospital Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

11.3 Retail Pharmacies

11.3.1 Overview

11.3.2 Retail Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

11.4 Others

11.4.1 Overview

11.4.2 Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

12. South & Central America Epilepsy Market - Country Analysis

12.1 South & Central America Epilepsy Market Overview

12.1.1 South & Central America: Epilepsy Market Breakdown, by Key Country, 2022 and 2030 (%)

12.1.1.1 Brazil: Epilepsy Market Overview

12.1.1.2 Brazil: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

12.1.1.2.1 Brazil: Epilepsy Market Breakdown, by Type

12.1.1.2.2 Brazil: Epilepsy Market Breakdown, by Route of Administration

12.1.1.2.3 Brazil: Epilepsy Market Breakdown, by Treatment Type

12.1.1.2.4 Brazil: Epilepsy Market Breakdown, by Age Group

12.1.1.2.5 Brazil: Epilepsy Market Breakdown, by Distribution Channel

12.1.1.3 Argentina: Epilepsy Market Overview

12.1.1.4 Argentina: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

12.1.1.4.1 Argentina: Epilepsy Market Breakdown, by Type

12.1.1.4.2 Argentina: Epilepsy Market Breakdown, by Route of Administration

12.1.1.4.3 Argentina: Epilepsy Market Breakdown, by Treatment Type

12.1.1.4.4 Argentina: Epilepsy Market Breakdown, by Age Group

12.1.1.4.5 Argentina: Epilepsy Market Breakdown, by Distribution Channel

12.1.1.5 Rest of South & Central America: Epilepsy Market Overview

12.1.1.6 Rest of South & Central America: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

12.1.1.6.1 Rest of South & Central America: Epilepsy Market Breakdown, by Type

12.1.1.6.2 Rest of South & Central America: Epilepsy Market Breakdown, by Route of Administration

12.1.1.6.3 Rest of South & Central America: Epilepsy Market Breakdown, by Treatment Type

12.1.1.6.4 Rest of South & Central America: Epilepsy Market Breakdown, by Age Group

12.1.1.6.5 Rest of South & Central America: Epilepsy Market Breakdown, by Distribution Channel

13. Industry Landscape

13.1 Overview

13.2 Growth Strategies in Epilepsy Market

13.3 Organic Growth Strategies

13.3.1 Overview

13.4 Inorganic Growth Strategies

13.4.1 Overview

14. Company Profiles

14.1 Abbott Laboratories

14.1.1 Key Facts

14.1.2 Business Description

14.1.3 Products and Services

14.1.4 Financial Overview

14.1.5 SWOT Analysis

14.1.6 Key Developments

14.2 Pfizer Inc

14.2.1 Key Facts

14.2.2 Business Description

14.2.3 Products and Services

14.2.4 Financial Overview

14.2.5 SWOT Analysis

14.2.6 Key Developments

14.3 Eisai Co Ltd

14.3.1 Key Facts

14.3.2 Business Description

14.3.3 Products and Services

14.3.4 Financial Overview

14.3.5 SWOT Analysis

14.3.6 Key Developments

14.4 UCB SA

14.4.1 Key Facts

14.4.2 Business Description

14.4.3 Products and Services

14.4.4 Financial Overview

14.4.5 SWOT Analysis

14.4.6 Key Developments

14.5 LivaNova Plc

14.5.1 Key Facts

14.5.2 Business Description

14.5.3 Products and Services

14.5.4 Financial Overview

14.5.5 SWOT Analysis

14.5.6 Key Developments

14.6 Novartis AG

14.6.1 Key Facts

14.6.2 Business Description

14.6.3 Products and Services

14.6.4 Financial Overview

14.6.5 SWOT Analysis

14.6.6 Key Developments

14.7 Medtronic Plc

14.7.1 Key Facts

14.7.2 Business Description

14.7.3 Products and Services

14.7.4 Financial Overview

14.7.5 SWOT Analysis

14.7.6 Key Developments

14.8 GSK Plc

14.8.1 Key Facts

14.8.2 Business Description

14.8.3 Products and Services

14.8.4 Financial Overview

14.8.5 SWOT Analysis

14.8.6 Key Developments

14.9 H. Lundbeck AS

14.9.1 Key Facts

14.9.2 Business Description

14.9.3 Products and Services

14.9.4 Financial Overview

14.9.5 SWOT Analysis

14.9.6 Key Developments

15. Appendix

15.1 About The Insight Partners

 

 

 

List of Tables

Table 1. South & Central America Epilepsy Market Segmentation

Table 2. Cell Therapy Approach - An Overview

Table 3. Gene Therapy Approach - An Overview

Table 4. Encapsulated cell bio delivery (ECB) system Cell and Gene Therapy Approach - An Overview

Table 5. Preclinically Tested Genetic Therapies for Epilepsy

Table 6. Clinical Trials for Epilepsy Gene Therapy: Overview

Table 7. Viral Vectors Comparison with respect to Various Parameters

Table 8. Subfamilies of Human K+ Channels Involved in Epilepsies

Table 9. Enzyme-Inducing Antiepileptic Drugs

Table 10. Enzyme-Inducing Antiepileptic Drugs & Drug Target Types Overview

Table 11. Brazil: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type

Table 12. Brazil: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration

Table 13. Brazil: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type

Table 14. Brazil: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group

Table 15. Brazil: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel

Table 16. Argentina: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type

Table 17. Argentina: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration

Table 18. Argentina: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type

Table 19. Argentina: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group

Table 20. Argentina: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel

Table 21. Rest of South & Central America: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type

Table 22. Rest of South & Central America: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration

Table 23. Rest of South & Central America: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type

Table 24. Rest of South & Central America: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group

Table 25. Rest of South & Central America: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel

Table 26. Recent Organic Growth Strategies in Epilepsy Market

Table 27. Recent Inorganic Growth Strategies in the Epilepsy Market

?

List of Figures

Figure 1. South & Central America Epilepsy Market Segmentation, by Country

Figure 2. Epilepsy Market - Key Market Dynamics

Figure 3. Impact Analysis of Drivers and Restraints

Figure 4. Epilepsy Market Revenue (US$ Million), 2020-2030

Figure 5. Epilepsy Market Share (%) - by Type (2022 and 2030)

Figure 6. Progressive Myoclonic Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

Figure 7. Reflex Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

Figure 8. Generalized Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

Figure 9. Other: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

Figure 10. Epilepsy Market Share (%) - by Route of Administration (2022 and 2030)

Figure 11. Oral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

Figure 12. Parenteral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

Figure 13. Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

Figure 14. Epilepsy Market Share (%) - by Treatment Type (2022 and 2030)

Figure 15. First Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

Figure 16. Second Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

Figure 17. Third Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

Figure 18. Epilepsy Market Share (%) - by Age Group (2022 and 2030)

Figure 19. Adult: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

Figure 20. Children: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

Figure 21. Epilepsy Market Share (%) - by Distribution Channel (2022 and 2030)

Figure 22. Hospital Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

Figure 23. Retail Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

Figure 24. Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

Figure 25. South & Central America: Epilepsy Market, By Key Country - Revenue (2022) (US$ Million)

Figure 26. South & Central America: Epilepsy Market Breakdown, by Key Countries, 2022 and 2030 (%)

Figure 27. Brazil: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)

Figure 28. Argentina: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)

Figure 29. Rest of South & Central America: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)

Figure 30. Growth Strategies in Epilepsy Market

 

 

?

  1. Abbott Laboratories
  2. Pfizer Inc
  3. Eisai Co Ltd
  4. UCB SA
  5. LivaNova Plc
  6. Novartis AG
  7. Medtronic Plc
  8. GSK Plc
  9. H. Lundbeck AS
  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the South & Central America epilepsy market.
  • Highlights key business priorities in order to assist companies to realign their business strategies.
  • The key findings and recommendations highlight crucial progressive industry trends in the South & Central America epilepsy market, thereby allowing players across the value chain to develop effective long-term strategies.
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
  • Scrutinize in-depth South & Central America market trends and outlook coupled with the factors driving the South & Central America epilepsy market, as well as those hindering it.
  • Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.
Report Code
Full Name
Country Name
Email Id
Phone Number
Job Title
Company
Requirement

Note : Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.


Purchase Options
Single User License
$3550
$2485
Site License
$4550
$3185
Enterprise License
$5550
$3885